Disinfectant Solution Demonstrates Potent Activity Against Bacteria and Fungi

[Guest guest]

Biofilms are slime like aggregations of bacteria or fungi and are

known to be far more difficult to eradicate than free living

bacteria or fungi.

Ceragenix Contact Lens Disinfectant Solution Demonstrates Potent

Activity Against Bacteria and Fungi

Mar 5 2007, 7:45 AM EST

Business Wire

http://www.genengnews.com/news/bnitem.aspx?name=13774134

Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP), a biopharmaceutical

company focused on infectious disease and dermatology, today

announced that Dr. B. Savage, a M. Izatt Professor of

Chemistry and Biochemistry at Brigham Young University (BYU),

presented data on the use of Ceragenins for ophthalmic

applications at the 1st Asia-ARVO meeting organized by the Singapore

Eye Research Institute on March 2, 2007 in Singapore.

The in vitro data presented at the conference demonstrated that:

1) A developmental Ceragenin-based contact lens disinfectant

solution was able to virtually eradicate within 1.5 hours,

all five strains of bacteria and fungi, according to the

test specified under the FDA's guidance document for

approval of contact lens disinfectant solutions - also

known as the " stand-alone " test.

2) When the Ceragenin-based contact lens disinfectant

solution

was compared to the two leading brands on the market in

its

ability to kill a strain of the fungal pathogen fusarium

solani, the Ceragenin solution showed a 4.19 log reduction

(the limit of detection) at 1.5 hours of soaking versus

0.48 and 0.26 log reductions for the two leading brands.

At six hours, the two comparators achieved log reductions

of 3.07 and 0.83 log reductions, while the Ceragenin

solution had completely killed the fungus by 1.5 hours.

A 1.0 log reduction is equal to a 90% kill, leaving 10% of

the fungi still viable. A 4.0 log reduction is equal to a

99.99% kill (the limit of detection in this test was 4.19

log which the Ceragenin solution achieved). The fungal

pathogen fusarium solani was the organism responsible for

last year's worldwide outbreak of eye infections that

resulted in a voluntary recall of a leading brand of

contact lens disinfectant solution.

3) When tested against a strain of fungal biofilm (candida),

the Ceragenin solution was able to virtually eradicate the

biofilm within six hours (a 6.0 log reduction), while two

of the three leading commercial brands tested in the same

test achieved log reductions of under 1.0 log and the

third

achieved a log reduction of under 2.0 logs. Biofilms are

slime like aggregations of bacteria or fungi and are known

to be far more difficult to eradicate than free living

bacteria or fungi.

In his presentation, Dr. Savage identified three areas of potential

use of Ceragenins in ophthalmology:

1) use in contact lens disinfectant solution to provide

optimal protection against bacterial and fungal pathogens;

2) use to treat contact lens storage cases to help prevent

the

growth of biofilms on storage containers (as a potential

reservoir for infection); and

3) use to treat disposable contact lenses and intraocular

lenses to provide an anti-infective surface on the lens

material to help reduce the risk of infection.

S. Porter, CEO of Ceragenix, stated, " We are encouraged by

the results of the recent testing carried out by independent

laboratories which have shown this excellent activity against ocular

pathogens. The worldwide market for contact lens disinfectant

solutions is in excess of $1 billion annually and if further studies

show similar effectiveness, we believe a Ceragenin-based contact

lens disinfectant solution may help reduce the risk of infection

among contact lens wearers. Encouraged by these results, we plan to

seek a partner to assist in further testing and commercialize this

opportunity in ophthalmology. "

Any ophthalmolic application of Ceragenin-based solution or products

will require approval from the United States Food and Drug

Administration (FDA). Ceragenix has not yet filed an application

with the FDA seeking clearance to market any ophthalmolic products.

About Ceragenix

Ceragenix Pharmaceuticals, Inc. is a biopharmaceutical company that

discovers, develops and commercializes novel anti-infective drugs

based on its proprietary class of compounds, Ceragenins (or CSAs).

Active against a broad range of gram positive and negative bacteria,

these agents are being developed as anti-infective medical device

coatings and as therapeutics for antibiotic-resistant organisms.

Ceragenix also owns exclusive rights to Barrier Repair Technology

for the treatment of dermatological disorders including atopic

dermatitis, neonatal skin disorders and others. Ceragenix's patented

Barrier Repair Technology, invented by Dr. Elias and licensed

from the University of California, is the platform for the

development of two prescription topical creams--EpiCeram and

NeoCeram. For additional information on Ceragenix, please visit

www.ceragenix.com.

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements. The

Private Securities Litigation Reform Act of 1995 provides a safe

harbor for forward-looking statements. These forward-looking

statements are subject to risks and uncertainties that may cause

actual results to differ materially from those expressed or implied

by such forward-looking statements, including, but not limited to,

the following: the ability of the company to raise sufficient

capital to finance its planned activities; the ability of the

Company to satisfy its outstanding convertible debt obligations;

receiving the necessary marketing clearance approvals from the

United States Food and Drug Administration; successful clinical

trials of the company's planned products including; the ability to

enroll the studies in a timely manner, patient compliance with the

study protocol, a sufficient number of patients completing the

studies; the ability of the company to commercialize its planned

products; the ability of the company to consummate a favorable

marketing agreement with a partner to market EpiCeram; market

acceptance of the company's planned products, the company's ability

to successfully develop its licensed compounds, alone or in

cooperation with others, into commercial products, the ability of

the company to successfully prosecute and protect its intellectual

property, and the company's ability to hire, manage and retain

qualified personnel. The aforementioned factors do not represent an

all inclusive list. Actual results, performance or achievements

could differ materially from those contemplated, expressed or

implied by the forward-looking statements contained in this press

release. In particular, important factors that could cause actual

results to differ materially from the company's forward-looking

statements include general economic factors, business strategies,

the state of capital markets, regulatory conditions, and other

factors not currently known to the company, may be significant, now

or in the future, and these factors may affect the company to a

greater extent than indicated. All forward-looking statements

attributable to the company or persons acting on its behalf are

expressly qualified in their entirety by the cautionary statements

set forth in this press release and in other documents that the

company files from time to time with the Securities and Exchange

Commission including its Annual Report on Form 10-KSB, Quarterly

Reports on Form 10-QSB and Current Reports on Form 8-KSB to be filed

in 2007. Except as required by law, the company does not undertake

any obligation to update any forward-looking statement, whether as a

result of new information, future events or otherwise.